Basic research for the prevention of cisplatin-induced renal toxicity based on the characteristics of renal tubular transport of its cytotoxic metabolite

基于顺铂细胞毒性代谢产物肾小管转运特性预防顺铂肾毒性的基础研究

• 批准号: 22790153
• 负责人: IWAMOTO Takuya
• 金额: $ 2.58万
• 依托单位: Mie University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22790153/
• 关键词: シスプラチン; 腎障害; 薬物トランスポータ; システイン複合体

This study was performed to investigate the characteristics of renal tubular transport of N-acetylcysteine conjugate of cisplatin(CDDP-NAC, cytotoxic metabolite). In the human embryonic kidney 293(HEK293) cells transfected OCT2, OAT1 or OAT3, the CDDP-NAC accumulation in these cells was significantly lower than that of CDDP alone. NAC treatment prevented CDDP uptake in renal tubular cells, which might contribute to the reduced toxicity of CDDP.

研究顺铂N-乙酰半胱氨酸结合物(CDDP-NAC，细胞毒性代谢物)的肾小管转运特性。在转导OCT2、OAT1或OAT3的人胚胎肾293(HEK293)细胞中，CDDP-NAC在这些细胞中的积聚明显低于单独转染CDDP。NAC可抑制CDDP在肾小管上皮细胞的摄取，这可能是CDDP毒性降低的原因之一。

项目成果

Concomitant use of itraconazole, a CYP3A4 inhibitor, increases the severity of peripheral neuropathy and thrombocytopenia induced by a protea some inhibitor, bortezomib

同时使用伊曲康唑（一种 CYP3A4 抑制剂）会增加由 Protea some 抑制剂硼替佐米引起的周围神经病变和血小板减少症的严重程度

• 发表时间: 2010
• 期刊: Pharmacotherapy
• 影响因子: 4.1
• 作者: Iwamoto T;Ishibashi M;Fujieda A;Masuya M;Katayama N;Okuda M
• 通讯作者: Okuda M

Altered function and expression of organic cation transporters, rOCT1 and rOCT2, in acute cholestasis and their implications in the disposition and clearances of drugs

急性胆汁淤积中有机阳离子转运蛋白 rOCT1 和 rOCT2 功能和表达的改变及其对药物处置和清除的影响

• 发表时间: 2010
• 作者: Kurata;et al.
• 通讯作者: et al.

Elevated Systemic Elimination of Cimetidine in Rats with Acute Biliary Obstruction: The Role of Renal Organic Cation Transporter OCT2

• DOI: 10.2133/dmpk.dmpk-10-rg-004
• 发表时间: 2010-01-01
• 期刊: DRUG METABOLISM AND PHARMACOKINETICS
• 影响因子: 2.1
• 作者: Kurata, Tomohiko;Muraki, Yuichi;Okuda, Masahiro
• 通讯作者: Okuda, Masahiro

Hepatic Drug Interaction Between Tacrolimus and Lansoprazole in a Bone Marrow Transplant Patient Receiving Voriconazole and Harboring CYP2C19 and CYP3A5 Heterozygous Mutations

接受伏立康唑且携带 CYP2C19 和 CYP3A5 杂合突变的骨髓移植患者中他克莫司和兰索拉唑之间的肝脏药物相互作用

• 发表时间: 2011
• 期刊: Clin Ther
• 影响因子: 3.2
• 作者: Iwamoto T;Monma F;Fujieda A;Nakatani K;Katayama N;Okuda M
• 通讯作者: Okuda M

がん薬物治療に伴う有害反応の発現機構と要因分析に関する研究

肿瘤药物治疗不良反应发生机制及因素分析研究

• 发表时间: 2011
• 期刊: 医療薬学
• 作者: 藤岡孝志;松永直哉;小柳悟;大戸茂弘;岩本卓也
• 通讯作者: 岩本卓也